The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients.

Adverse effects of antituberculosis agents such as hepatotoxicity may reduce treatment effectiveness, because they significantly contribute to nonadherence and eventually result in treatment failure, relapse or the emergence of drug resistance. Garlic is an ancient herbal substance, which its effectiveness on isoniazid and rifampicin-induced hepatic injury in animal models has been demonstrated (1). In the present study a randomized, double blind, placebo-controlled, parallel group clinical trial was designed to assess the effect(s) of garlic tablets (1000 mg daily) administered for two weeks orally. Fifty eight newly diagnosed, smear positive pulmonary tuberculosis patients, with age ranges between 18-65 years old, were randomly allocated into two groups. Each patient received either garlic or placebo tablets for the first two weeks of tuberculosis treatment. Of total 58 patients, 31 received garlic tablets while 27 received placebo. No significant difference was found between the two groups regarding age, sex, nationality, smoking, underlying diseases and opium usage. During 8 weeks of anti-TB (antituberculosis) treatment, 8 (13.0%) patients developed drug-induced hepatotoxicity (DIH). Of them, 6 (75%) occurred in the first two weeks of treatment. Fifty percent of the patients who developed DIH were in garlic group. Results indicated no significant difference between groups in developing DIH (p=1.000). We could not show a significant role in preventing DIH by 1000 mg daily garlic administration.

RCT Entities:   Population Interventions Outcomes

Introduction

Tuberculosis (TB) is one of the principal reasons of mortality from an infectious disease. About 8.6 million new TB cases were reported in 2012 and 1.3 million of them died (2). Hepatic damage is the most serious adverse effect of antituberculosis treatment and has a high rate in some developing countries such as Iran, where the reported rates vary from 4.9% to 27.7% (3, 4, 5). The incidence of 13% was indicated at the national TB referral center (6).

Isoniazid (INH), rifampicin (RIF) and pyrazinamide are potentially hepatotoxic drugs. Antituberculosis drug-induced hepatotoxicity (DIH) causes considerable morbidity and mortality and diminishes treatment effectiveness. It significantly adds on issues such as non adherence, treatment failure, relapse or the emergence of drug resistance (7). It frequently requires treatment modification, which may have negative consequences for treatment outcome. Asymptomatic liver enzymes elevation is common during antituberculosis treatment, but hepatotoxicity can be fatal when not recognized in early stages (8).

Studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by using agents with antioxidant properties such as N-acetylcysteine (9). Freshly prepared garlic homogenate, which has an antioxident effect, has also been shown to have a protective effect against INH+RIF-induced liver injury in animal models (1, 10). However, there are no published data regarding the protective effect of garlic against antituberculosis DIH in humans, if any, to our knowledge.

Hence, this clinical trial was designed to study the effect of garlic on DIH in newly diagnosed tuberculosis patients.

Experimental

Setting

The study was carried out at Masih Daneshvari hospital from March to September 2009. This tertiary center is the sole national referral hospital for TB, holds the national reference laboratory, comprises the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Tehran, Iran and serves as the WHO collaborating center in the Middle East region(6).

Case recruitment

Written informed consent was obtained from all of the participants.

Fifty eight inpatients, 18-65 years old, who were newly diagnosed with smear positive pulmonary tuberculosis completed the study. They all received standard antituberculosis regimen.

Patients with positive HIV, confirmed hepatitis, cirrhosis, renal failure and known hypersensitivity to garlic and those prone to hemorrhage and/or hypotension were excluded.

Treatment and monitoring

A randomized, double blind, placebo-controlled, parallel group, clinical trial was designed to assess the treatment effects of garlic tablets administered for two weeks orally.

This clinical trial was registered in the Australian New Zealand Clinical Trial Registry, and the registry number is ACTRN12609000703202.

Patients were randomly allocated into two groups. The treatment allocation was randomized by a researcher who was not directly involved in the trial and computerized method was used to generate the sequence in which subjects would be randomized. The treatment group received 2 tablets (1000 mg) of Garcin (Gol Daru, Isfahan, Iran) per day for the first 2 weeks of the standard anti-tuberculosis regimen. For the placebo group, identical lactose pills manufactured by the same company were administered daily for the same period of time. Since the placebo pills lack the smell of the real drug, the treatment tablets were put in the vicinity of the plastic bags for a week and then the bags were filled by placebo.

Patients’ sputum smears were monitored at baseline, 4 and 8 weeks. Also the clinical symptoms and liver function tests including Serum Glutamic Oxaloacetic Transaminase (SGOT), Serum Glutamic Pyruvic Transaminase (SGPT), and alkaline phosphatase were monitored at baseline, 2, 4 and 8 weeks due to the fact that drug-induced hepatotoxicity is considered when alanine amino transferase levels are increased up to three times the upper limit of normal (ULN) in the presence of hepatitis symptoms or elevation of up to five times the ULN in the absence of symptoms (11).

Statistical analysis

Fisher’s exact test was used to assess the effects of garlic on reducing the rate of antituberculosis DIH compared to the placebo.

To describe the relationship between the outcome and the set of independent variables logistic regression model was used but due to limited sample size, the achieved model was not satisfactory. p-values ≤0.05 was used as significance level.

Results

Figure 1. represents the flow diagram of our patients. Fifty eight new cases of tuberculosis were included and analysed in the study. Patients’ characteristics and clinical factors are summarized in Table 1. Of the total 58 patients who completed the study protocol, 31 received garlic tablets while other 27 received placebo.

Figure 1

Flow Diagram of the patients

Table 1

Patients’ characteristics and clinical factors

Patients’ characteristics	Total patients (%)	Treatment group (%)	Placebo group (%)	p-Value
Total	58	31	27
Sex
MaleFemale	21(36.2)37(63.8)	11(35.5)20(64.5)	10(37)17(63)	NS
Age
RangeMedian	17-7035.53	17-6337.25	18-7035.55	NS
Nationality
IranianAfghan	34(58.6)24(41.4)	17(54.8)14(45.2)	17(63)10(37)	NS
Patient class
Smear positiveOther	21(36.2)37(63.8)	12(38.7)19(61.3)	9(33.3)18(66.7)	NS
Underlying disease
Diabetes MellitusChronic Renal FailureIschemic Heart DiseaseOther	7(12.1)1(1.8)2(3.6)12(20.7)	3(9.7)0(0)2(6.4)4(12.9)	4(14.8)1(3.7)0(0)8(29.6)	NS
Smoking
Active smokerPassive smokerNone	9(15.5)1(1.8)48(82.8)	4(12.9)1(3.2)26(83.9)	5(18.5)0(0)22(81.5)	NS
Opium inhalation
YesNo	8(13.8)50(86.2)	4(12.9)27(87.1)	4(14.8)23(85.2)	NS
Drug-induced hepatitis	8(13.8)	4(12.9)	4(14.8)	NS
Hepatitis follow-up
2nd week follow-up4th week follow-up8th week follow-up	6(75)1(12.5)1(12.5)	3(9.7)0(0)1(3.2)	3(11.1)1(3.7)0(0)	NS
Outcome
Under treatmentCuredFailureComplete treatment	25(43.1)21(36.2)3(5.2)9(15.5)	16(51.6)10(32.3)1(3.2)4(12.9)	9(33.3)11(40.7)2(7.4)5(18.5)	NS

Males comprised 21 (36.2%) of the cases. Thirty four (58.6%) of the patients were Iranian and the remaining 24 (41.4%) were Afghan. Nine (15.5%) patients were active smokers while 48 (82.8%) were non smokers and one was passive smoker. No significant difference was found between groups regarding age, sex, nationality, smoking, underlying diseases and opium addiction. During 8 weeks of anti-TB treatment, 8 (13.0%) patients developed drug-induced hepatitis (DIH), 6 (75%) of them did so in the first two weeks of treatment, 1 (12.5%) between two and four weeks and 1 (12.5%) between four and eight weeks from the initiation of the treatment.

Four of 8 (50%) patients who developed DIH were in the treatment group. There was no significant difference between patients with hepatitis and without hepatitis considering variables i.e. age, sex, nationality, smoking, underlying diseases and opium inhalation (Table 2).

Table 2

Patients’ characteristics due to developing DIH

Patients’ characteristics	Drug-induced hepatitis (%)	Without hepatitis (%)	p-Value
Total	8	50
Sex
MaleFemale	3(37.5)5(62.5)	18(36)32(64)	NS
Age
RangeMedian	17-5134.5	17-7035.7	NS
Nationality
IranianAfghan	4(50)4(50)	30(60)20(40)	NS
Patient class
Smear positiveOther	4(50)4(50)	17(34)33(66)	NS
Underlying disease
Diabetes MellitusChronic Renal FailureIschemic Heart DiseaseOther	1(12.5)0(0)0(0)3(37.5)	6(12)1(2)2(4)9(18)	NS
Smoking
Active smokerPassive smokerNone	0(0)1(12.5)7(87.5)	9(18)0(0)41(82)	NS
Opium inhalation
YesNo	0(0)8(100)	8(16)42(84)	NS
Outcome
Under treatmentCuredFailureComplete treatment	4(50)3(37.5)1(12.5)0(0)	21(42)18(36)2(4)9(18)	NS

Results indicated no significant difference between the two groups in developing DIH (p=1.000).

Discussion

In the present study the probable protective effect of garlic on decreasing the drug-induced hepatotoxicity in newly diagnosed tuberculosis inpatients was investigated.

Patients received garlic or placebo for 2 weeks from the initiation of the treatment. All the patients were precisely monitored regarding clinical and laboratory parameters for the first two months of treatment. As it was presumed 6 out of 8 patients developed drug-induced hepatotoxicity during the first 2 weeks. Studies indicated that DIH most often occurs during the first 2 weeks of anti-TB treatment (6). No significant difference was shown regarding variables (age, sex, nationality, smoking, underlying diseases and opium inhalation using analytical methods), between patients who developed DIH and those who did not four of 8 patients who developed DIH were in garlic group. Statistical analysis indicated no significant difference between the treatment group and placebo group in developing antituberculosis DIH despite receiving garlic for two weeks. Consequently, our study could not confirm the protective effect of garlic administration against DIH, however, a variety of antioxidants are found in garlic, which may make this drug eligible to prevent disease-causing oxidative harm (12). Metabolism pathways and toxic metabolites of anti-TB agents play a central role in hepatotoxicity of these agents (13). Garlic and the related organosulfur compounds have antioxidant and detoxifying properties. These detoxifying effects are due to their inhibiting effect on phase I enzymes and induction of phase II enzymes via binding to exogenous toxins through sulfhydryl groups (12).

Garlic can inhibit lipid peroxidases. Garlic beneficial effect in saving the liver from substance induced damage may be through its additional advantages of lowering the plasma lipids (14). While we were unable to show any clinical effect of the drug in our patient population.

Previous studies on the mechanism of INH+RIF-induced hepatotoxicity have shown that non-protein thiols play a crucial role in the detoxification of reactive toxic metabolites. Liver injury is more prevalent when glutathione stores are noticeably depleted. It has been indicated that garlic involves in modulation of the glutathione-related antioxidant system. An increase in glutathione s-transferase activity and a decrease in glutathione peroxidase activity were noted in garlic-treated rats (1, 15).

Non-protein thiol is considered a defense mechanism in living cells. It protects cellular elements from peroxidase formed during metabolism and other reactive oxygen species reactions, since it acts as a substrate for antioxidant enzymes i.e. glutathione peroxidase and glutathione reductase. Garlic extract increases cellular glutathione in a variety of cells including those in liver (16).

Our inability in showing its positive impact, if any, on reducing the rate of hepatitis may be due to different reasons. Our study population was limited in size. In spite of the fact that the rate of hepatitis in our studied patients was almost the same as previously reported studies, the number of the patients with DIH (8 totally) may be insufficient to demonstrate the likely impact. Also the dose and duration of the treatment should be reevaluated for future researches.